INmune Bio (NASDAQ:INMB) Rating Lowered to “Sell” at Wall Street Zen

INmune Bio (NASDAQ:INMB) was downgraded by stock analysts at Wall Street Zen from a “hold” rating to a “sell” rating in a research report issued to clients and investors on Saturday.

INmune Bio Stock Up 6.3%

INMB opened at $1.51 on Friday. The company’s 50-day moving average price is $1.70 and its two-hundred day moving average price is $1.91. INmune Bio has a twelve month low of $1.38 and a twelve month high of $11.64. The stock has a market cap of $40.14 million, a price-to-earnings ratio of -0.71 and a beta of 0.72.

Institutional Inflows and Outflows

A number of institutional investors have recently made changes to their positions in INMB. Intech Investment Management LLC bought a new position in shares of INmune Bio during the 2nd quarter worth $26,000. Cary Street Partners Financial LLC purchased a new stake in INmune Bio during the third quarter valued at about $29,000. Independent Advisor Alliance bought a new position in INmune Bio during the third quarter worth about $30,000. Squarepoint Ops LLC purchased a new position in shares of INmune Bio in the third quarter worth about $30,000. Finally, Modera Wealth Management LLC bought a new stake in shares of INmune Bio in the second quarter valued at approximately $36,000. Hedge funds and other institutional investors own 12.72% of the company’s stock.

About INmune Bio

INmune Bio, Inc is a clinical-stage immunology company based in San Diego, California, focused on harnessing the innate immune system to combat a range of serious diseases. The company’s research and development efforts concentrate on modulating cellular pathways to restore and enhance the body’s natural defenses, particularly in oncology and neurodegenerative conditions.

The company’s lead therapeutic candidate, XPro1595 (also referred to as INB03), is a proprietary selective inhibitor of soluble tumor necrosis factor (TNF) designed to reduce chronic inflammation without impairing membrane-bound TNF functions.